Raymond James Financial Inc. bought a new stake in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Free Report) during ...

AlphaQuest LLC increased its position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Free Report) by 969.6% in the 4th quarter ...

LIVMARLI, an IBAT inhibitor, is approved for the treatment of two rare liver diseases affecting children and adults. It is approved for the treatment of cholestatic pruritus in patients with ...

(Nasdaq: MIRM) today announced that on March 10, 2025, the Compensation Committee of Mirum’s Board of Directors granted ...

Volixibat, an IBAT inhibitor, is being evaluated in two potentially registrational studies including the Phase 2 VISTAS study for primary sclerosing cholangitis (PSC) and Phase 2b VANTAGE study ...

FOSTER CITY, Calif., March 11, 2025--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on March 10, 2025, the Compensation Committee of Mirum’s Board of Directors ...

LIVMARLI, an IBAT inhibitor, is approved for the treatment of two rare liver diseases affecting children and adults. It is approved for the treatment of cholestatic pruritus in patients with ...

The once-daily, non-systemic ileal bile acid transport (IBAT) inhibitor was recommended for approval by the EMA's human medicines committee, the CHMP, in July 2023 for this indication under the ...

And so we have been able to pick up IBAT treatment naive PFIC patients ... dramatic response that you can drive on itch with an iDAT inhibitor, we can use that as an outcome in our program.